1800 244 735

Helpline (02) 9874 9777

The structure of the protein that causes Huntington's disease, revealed

The cause of Huntington’s disease has been known since 1993, but the physical structure of the healthy huntingtin protein proved difficult to discover until now. German scientists have now revealed the shape of the huntingtin protein for the first time. Although the structure of the mutant form of the protein was not investigated, this study provides an excellent platform to build upon and will boost drug development efforts.

Know your enemy

One of the biggest issues in HD research to date is that although we know what causes the disease – a harmful protein called mutant huntingtin. We even know some ways in which the mutant protein wreaks havoc within the human brain. But until now we’ve had no idea what the protein actually looks like. That makes trying to prevent it causing damage very difficult! Imagine you’re a farmer whose crops are being damaged by an animal every night. If you had a photo of the animal that was causing the damage, it would be easier to figure out how to prevent it. A drunk elephant would require a different strategy from a swarm of locusts. It’s the same when we’re fighting brain diseases: knowing what a protein looks like is a huge help when it comes to understanding how it operates and how to make drugs to change its behaviour.

Cool science – literally

The technique used in this particular study is the crème de la crème of microscopy, so much so that it was awarded the Nobel Prize for Chemistry last year. It’s called cryo-electron microscopy, otherwise known as cryo-EM. It involves shooting a beam of electrons at a sample that’s been frozen using a super-cold liquid. When we say cool we don’t mean like a beer or a smoothie – this technique involves cooling proteins to several hundred degrees below freezing.

When the electrons hit the sample, it causes them to scatter slightly before striking an electron detector, which builds up an image like the light detector in a digital camera. But one image isn’t enough – hundreds of ‘photos’ have to be taken from different angles, then combined by computer to reveal the 3D shape of the protein.

The images generated by cryo-EM are so precise that the authors of this study – a team led by Stefan Kochanek at the University of Ulm – were able to document the structure of huntingtin down to a billionth of a centimetre! The study found that the protein was essentially composed of two parts, connected by a bridge region. This is a very important finding as it suggests that the function of huntingtin could be to act as a kind of protein hub. In other words, it’s a mothership that lots of different protein spaceships dock into.

What’s the big deal?

You might be thinking to yourself, why has it taken such a long time to figure this out? Basically, it’s due to how complicated and bendy the huntingtin protein is. In order to build up a 3D image of the protein, it has to be photographed from multiple different angles, but for the pieces of the puzzle to slot together perfectly, the protein has to remain in the same position for this entire process. Unfortunately for us, this doesn’t happen with the huntingtin protein alone. To get around this, the researchers of this study used another protein called ‘huntingtin-associated protein 40’ or HAP40, which was able to bind to both segments of HTT as well as the bridge region and essentially fix it in one position, to stop it moving around. This stabilised the protein for long enough that the ‘photoshoot’ could take place.

What about the mutant protein?

The structure that was just announced was of the normal, healthy huntingtin protein that scientists call ‘wild-type’. But what about the structure of mutant huntingtin? Surely we need to know the what that protein looks like, to actually help in HD?

On the one hand yes, there is still an urgent need to identify the structure of the harmful version of huntingtin, and that would be super-helpful for designing therapies to combat the mutant protein’s harmful effects. However, that poses a whole host of other potential challenges to researchers.

Unfortunately, the presence of the mutation changes the the way the protein interacts with other proteins. That’s probably one of the things that makes it harmful. Remember that the success of the photoshoot depended on huntingtin sticking to another protein, HAP40. But the presence of the mutation may mean that huntingtin and HAP40 no longer stick together so well, meaning the cryo-EM photoshoot doesn’t work so well. The authors hinted at this problem in their article.

How can this help?

The structure of the mutant protein will hopefully come in time, now that the healthy one has shown its face. But just knowing the structure of the healthy huntingtin protein is already a big deal. Despite decades of research, we still don’t understand all the jobs huntingtin carries out in our cells, not just in the brain but the whole body. But since the structure of a protein basically dictates how it interacts with other molecules, we can now use these results to work out what different functions huntingtin might have, and how it achieves them. Essentially, this finding is a lightbulb that means we’re no longer shooting in the dark to understand and reveal huntingtin function.

Finally, this finding will be a big boost for efforts to invent new drugs to fight Huntington’s disease, especially if it does lead to uncovering what the mutant protein looks like. It could enable the design of targeted drugs that make the huntingtin protein less toxic whilst protecting the helpful functions of the healthy protein. Hopefully, this discovery will kickstart a new era for targeted drug development in Huntington’s disease, focused on the known structure of the huntingtin protein.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more